CATALYST PHARMACEUTICALS, INC. financials

  1. Home
  2. Financials
  3. CPRX
CPRX CIK 0001369568

Source: EDGAR filings · Built 2026-06-02T02:43:51Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 208.61M 239.25M 143.37M 116.02M 59.35M 45.02M
EBITDA 295.65M 232.90M 119.69M 103.08M 52.58M 41.40M
Working Capital 746.88M 502.93M 143.27M 263.22M 183.04M 136.49M
Net Debt -706.38M -514.37M -134.08M -294.50M -167.24M -130.21M
Gross Margin 85.19% 86.00% 86.95% 83.94% 84.46% 85.69%
Operating Margin 43.77% 39.68% 21.80% 47.54% 37.20% 34.69%
Net Margin 36.39% 33.33% 17.93% 38.79% 28.03% 62.97%
Return on Equity (ROE) 22.46% 22.52% 18.41% 27.65% 19.09% 44.21%
Return on Assets (ROA) 19.41% 19.25% 15.19% 22.12% 16.60% 38.98%
Current Ratio 6.08× 5.17× 2.88× 5.57× 7.76× 7.00×
Debt-to-Equity 0.00× 0.00× 0.01× 0.01× 0.02× 0.00×
Effective Tax Rate 24.40% 24.22% 24.44% 20.66% 25.03% -79.00%
Cash Conversion Ratio 0.97× 1.46× 2.01× 1.40× 1.53× 0.60×
Accruals Ratio 0.01× -0.09× -0.15× -0.09× -0.09× 0.16×
SBC % of Revenue 4.21% 4.53% 3.58% 3.69% 4.31% 5.26%
CapEx Coverage 3597.76× 431.31× 621.64× 4001.62× 59.13× 4094.00×
Free Cash Flow Per Share $1.64 $1.91 $1.26 $1.04 $0.55 $0.42

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 13.89× 15.93× 26.68× 24.80× 18.30× 4.70×
P/FCF 14.24× 10.90× 13.34× 17.86× 12.30× 7.88×
FCF Yield 7.02% 9.18% 7.50% 5.60% 8.13% 12.69%
EV / EBITDA 7.28× 8.62× 13.92× 16.14× 10.08× 5.23×
P/S 4.85× 5.13× 4.52× 9.14× 4.95× 2.91×
P/B 3.00× 3.47× 4.64× 6.52× 3.37× 2.04×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 588.99M 491.73M 398.20M 214.20M 140.83M 119.07M
Revenues — — — — — 119.07M
Cost of Goods and Services Sold 87.25M 68.84M 51.97M 34.39M 21.88M 17.04M
Research and Development Expense 12.71M 12.65M 93.15M 19.79M 16.94M 16.50M
Selling, General and Administrative Expense 193.75M 177.74M 133.71M 57.09M 49.63M 44.23M
Operating Expenses 206.46M 190.39M 226.86M 76.87M — —
Operating Income (Loss) 257.78M 195.12M 86.81M 101.84M 52.38M 41.30M
Income Tax Expense (Benefit) 69.19M 52.37M 23.10M 21.64M 13.19M -33.09M
Net Income (Loss) Attributable to Parent 214.33M 163.89M 71.41M 83.08M 39.48M 74.98M
Earnings Per Share, Basic $1.75 $1.38 $0.67 $0.80 $0.38 $0.72
Weighted Average Number of Shares Outstanding, Basic 122.29M 118.46M 106.28M 103.37M 103.38M 103.51M
Earnings Per Share, Diluted $1.68 $1.31 $0.63 $0.75 $0.37 $0.71
Weighted Average Number of Shares Outstanding, Diluted 127.26M 124.94M 113.75M 111.38M 107.80M 106.24M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 709.17M 517.55M 137.64M 298.39M 171.44M 130.24M
Assets, Current 894.03M 623.61M 219.33M 320.81M 210.11M 159.24M
Assets 1.10B 851.41M 470.11M 375.63M 237.79M 192.35M
Liabilities, Current 147.15M 120.68M 76.06M 57.59M 27.06M 22.76M
Liabilities 149.71M 123.78M 82.23M 75.21M 30.96M 22.76M
Stockholders' Equity Attributable to Parent 954.27M 727.63M 387.88M 300.42M 206.83M 169.60M
Common Stock, Shares, Outstanding 122.51M 120.88M 107.12M 105.26M 102.99M 103.78M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 208.67M 239.81M 143.60M 116.05M 60.37M 45.03M
Payments to Acquire Property, Plant, and Equipment 58.00K 556.00K 231.00K 29.00K 1.02M 11.00K
Net Cash Provided by (Used in) Investing Activities -58.00K -556.00K -293.50M 9.21M -11.02M -5.01M
Payments for Repurchase of Common Stock 25.30M 0 0 6.91M 12.09M —
Net Cash Provided by (Used in) Financing Activities -16.99M 140.66M -10.86M 1.69M -8.14M 702.00K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CPRX CIK 0001369568), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

EWBC

EAST WEST BANCORP, INC.

OII

OCEANEERING INTERNATIONAL INC

XRAY

DENTSPLY SIRONA Inc.